FDA Advisors Want More Data On Nanotech Sunscreens
This article was originally published in The Tan Sheet
Executive Summary
Members of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology say more light needs to be shed on nanotechnology. FDA officials tell the panel the agency’s knowledge of pharmaceutical firms’ use of nanotechnology still is developing, but maintain the products are safe.
You may also be interested in...
European Nanomaterial Definition Brings Measurement Challenges
The European Commission’s definition of “nanomaterial,” to potentially be used in legislation, appears to be relatively simple. In practice, measuring particles against the standard offers a number of technological challenges.
European Nanomaterial Definition Brings Measurement Challenges
The European Commission’s definition of “nanomaterial,” to potentially be used in legislation, appears to be relatively simple. In practice, measuring particles against the standard offers a number of technological challenges.
First FDA Center Of Excellence For Regulatory Science Looks At Nanotechnology
National Center for Toxicological Research signs agreement setting up CERS in Arkansas.